ATA-2271

N/A

Report date: 2025/06/13 20:00:59

Base Information

Drug NameATA-2271
Drug Alias NameAnti-mesothelin autologus chimeric antigen receptor T cell therapy (Atara Biotherapeutics)Anti-mesothelin CAR T cell therapy (Atara Biotherapeutics)Mesothelin-targeted CAR T immunotherapy (Atara Biotherapeutics)M28z1XXPD1DNR CAR T cells (Memorial Sloan Kettering Cancer Center)Mesothelin-targeted autologous CAR T (Atara Biotherapeutics) +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Mesothelin
TargetsMesothelin
Therapy Area/IndicationsEsophageal adenocarcinomaDiabetes MellitusStomach Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer CenterAtara Biotherapeutics IncBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer CenterBayer AG
Inactive CompaniesAtara Biotherapeutics Inc
Active IndicationsEsophageal adenocarcinomaDiabetes MellitusStomach Neoplasms +[7] 
Inactive IndicationsMesotheliomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A